T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Silicon Laboratories
SLAB
$7.3B
| $12.1M | ﹤0.01% |
58,767
-2,534
| -4% | -$467K |
|
1377
Cheniere Energy
LNG
$55B
| $12.1M | ﹤0.01% |
119,307
-5,858
| -5% | -$611K |
|
1378
Bloom Energy
BE
$69.6B
| $12M | ﹤0.01% |
548,283
+78,200
| +17% | +$1.98M |
|
1379
Douglas Dynamics
PLOW
$981M
| $12M | ﹤0.01% |
307,587
-150,999
| -33% | -$6.09M |
|
1380
Frontier Group Holdings
ULCC
$1.54B
| $11.8M | ﹤0.01% |
872,343
+525,799
| +152% | +$8.04M |
|
1381
Emergent Biosolutions
EBS
$233M
| $11.8M | ﹤0.01% |
272,073
-268,476
| -50% | -$12.1M |
|
|
VMW
1382
DELISTED
VMware, Inc
VMW
| $11.8M | ﹤0.01% |
102,029
+56,313
| +123% | +$7.4M |
|
1383
DXC Technology
DXC
$1.79B
| $11.7M | ﹤0.01% |
364,519
-14,415
| -4% | -$470K |
|
|
EB
1384
DELISTED
Eventbrite
EB
| $11.5M | ﹤0.01% |
658,933
-53,430
| -8% | -$989K |
|
1385
Norwegian Cruise Line
NCLH
$8.98B
| $11.4M | ﹤0.01% |
550,016
-50,159
| -8% | -$1.2M |
|
|
PBCT
1386
DELISTED
People's United Financial Inc
PBCT
| $11.4M | ﹤0.01% |
639,344
-26,420
| -4% | -$471K |
|
|
INFN
1387
DELISTED
Infinera Corporation Common Stock
INFN
| $11.4M | ﹤0.01% |
1,184,927
-18,635
| -2% | -$158K |
|
1388
Oxford Industries
OXM
$538M
| $11.3M | ﹤0.01% |
111,611
+7,439
| +7% | +$723K |
|
|
DISCK
1389
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $11.2M | ﹤0.01% |
488,168
-34,747
| -7% | -$837K |
|
|
OPTU
1390
Optimum Communications Inc
OPTU
$227M
| $11.2M | ﹤0.01% |
690,644
-46,457
| -6% | -$788K |
|
1391
TG Therapeutics
TGTX
$7.58B
| $11M | ﹤0.01% |
580,992
-844,156
| -59% | -$21.9M |
|
|
RDUS
1392
DELISTED
Radius Health, Inc.
RDUS
| $11M | ﹤0.01% |
1,594,047
-6,097,624
| -79% | -$89.5M |
|
1393
Guidewire Software
GWRE
$14.4B
| $11M | ﹤0.01% |
96,760
-7,681
| -7% | -$911K |
|
|
ZEN
1394
DELISTED
ZENDESK INC
ZEN
| $10.7M | ﹤0.01% |
102,860
-1,770,794
| -95% | -$190M |
|
|
XM
1395
DELISTED
Qualtrics International Inc. Class A Common Stock
XM
| $10.6M | ﹤0.01% |
300,607
+4,866
| +2% | +$189K |
|
1396
Plug Power
PLUG
$3.21B
| $10.5M | ﹤0.01% |
373,671
+62,938
| +20% | +$2.18M |
|
1397
Stoke Therapeutics
STOK
$2.02B
| $10.5M | ﹤0.01% |
438,247
+100,665
| +30% | +$2.4M |
|
1398
SelectQuote
SLQT
$126M
| $10.4M | ﹤0.01% |
1,151,328
-1,551,776
| -57% | -$17M |
|
|
POSH
1399
DELISTED
Poshmark, Inc. Class A Common Stock
POSH
| $10.3M | ﹤0.01% |
604,316
-626,274
| -51% | -$13.2M |
|
1400
Regenxbio
RGNX
$720M
| $10.2M | ﹤0.01% |
313,256
+18,311
| +6% | +$624K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.